Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease - PubMed (original) (raw)
Review
. 2017 Aug;92(2):306-312.
doi: 10.1016/j.kint.2017.02.035. Epub 2017 Jun 24.
Affiliations
- PMID: 28651951
- DOI: 10.1016/j.kint.2017.02.035
Free article
Review
Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease
Mai Sugahara et al. Kidney Int. 2017 Aug.
Free article
Abstract
Anemia is a common complication of chronic kidney disease and is mainly caused by the inability of injured kidneys to produce adequate amounts of erythropoietin. Studies elucidating the regulation of erythropoietin production led to the identification of hypoxia-inducible factor (HIF), which activates the transcription of genes that mediate adaptive responses to hypoxia. HIF is a heterodimer that consists of an α and β subunit. While HIF-β is constitutively expressed, HIF-α is subjected to ubiquitination and proteasomal degradation under normoxic conditions. This process is mediated by prolyl hydroxylase domain proteins, the inhibition of which results in an increased expression of hypoxia-induced genes, including erythropoietin. These findings led to the development of prolyl hydroxylase domain inhibitors as novel therapeutic agents against anemia in chronic kidney disease. Prolyl hydroxylase domain inhibition improves iron metabolism, which also contributes to erythropoiesis. To date, at least 6 small-molecule inhibitors of the prolyl hydroxylase domain have been tested in humans, and clinical trials have shown that they are effective without causing serious adverse events. However, there is a theoretical concern that the systemic activation of HIF could also induce deleterious effects such as tumorigenesis and severe pulmonary hypertension, which demands careful assessments in future clinical studies.
Keywords: anemia; erythropoietin; hypoxia-inducible factor; prolyl hydroxylase domain.
Copyright © 2017 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
Similar articles
- [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
Maruno S, Tanaka T, Nangaku M. Maruno S, et al. Rinsho Ketsueki. 2021;62(5):371-377. doi: 10.11406/rinketsu.62.371. Rinsho Ketsueki. 2021. PMID: 34108317 Japanese. - Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.
Kaplan JM, Sharma N, Dikdan S. Kaplan JM, et al. Int J Mol Sci. 2018 Jan 29;19(2):389. doi: 10.3390/ijms19020389. Int J Mol Sci. 2018. PMID: 29382128 Free PMC article. Review. - HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
Kular D, Macdougall IC. Kular D, et al. Pediatr Nephrol. 2019 Mar;34(3):365-378. doi: 10.1007/s00467-017-3849-3. Epub 2018 Mar 22. Pediatr Nephrol. 2019. PMID: 29569190 Free PMC article. Review. - Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease.
Hasegawa S, Tanaka T, Nangaku M. Hasegawa S, et al. Curr Opin Nephrol Hypertens. 2018 Sep;27(5):331-338. doi: 10.1097/MNH.0000000000000431. Curr Opin Nephrol Hypertens. 2018. PMID: 30067604 Review. - Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
Kurata Y, Tanaka T, Nangaku M. Kurata Y, et al. Curr Opin Nephrol Hypertens. 2020 Jul;29(4):414-422. doi: 10.1097/MNH.0000000000000617. Curr Opin Nephrol Hypertens. 2020. PMID: 32452915 Review.
Cited by
- Efficacy of daprodustat for patients on dialysis with anemia: systematic review and network meta-analysis.
Ali Fadlalmola H, Al-Sayaghi KM, Al-Hebshi AA, Alhujaily M, Alyamani AO, Alem AA, Syrafi MH, Alem S, Farhat AH, Mohamed FA, Abdalrahman HH, Abdelmalik MA, Abdalrhman NM, Eltayeb AM. Ali Fadlalmola H, et al. Pan Afr Med J. 2024 Mar 8;47:114. doi: 10.11604/pamj.2024.47.114.37278. eCollection 2024. Pan Afr Med J. 2024. PMID: 38828426 Free PMC article. Review. - Hypoxic Inducible Factor Stabilization in Pericytes beyond Erythropoietin Production: The Good and the Bad.
Troise D, Infante B, Mercuri S, Piccoli C, Lindholm B, Stallone G. Troise D, et al. Antioxidants (Basel). 2024 Apr 27;13(5):537. doi: 10.3390/antiox13050537. Antioxidants (Basel). 2024. PMID: 38790642 Free PMC article. Review. - Exposure to normobaric hypoxia shapes the acute inflammatory response in human whole blood cells in vivo.
Schönberger T, Jakobs M, Friedel AL, Hörbelt-Grünheidt T, Tebbe B, Witzke O, Schedlowski M, Fandrey J. Schönberger T, et al. Pflugers Arch. 2024 Sep;476(9):1369-1381. doi: 10.1007/s00424-024-02969-2. Epub 2024 May 7. Pflugers Arch. 2024. PMID: 38714572 Free PMC article. - Stabilizing Hypoxia-Inducible Factor to Manage Anemia in Chronic Kidney Disease: From Basic Theory to Clinical Study.
Wang Y, Yu X. Wang Y, et al. Kidney Dis (Basel). 2024 Jan 3;10(2):132-142. doi: 10.1159/000536039. eCollection 2024 Apr. Kidney Dis (Basel). 2024. PMID: 38659701 Free PMC article. Review. - Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association.
Stoumpos S, Crowe K, Sarafidis P, Barratt J, Bolignano D, Del Vecchio L, Małyszko J, Więcek A, Ortiz A, Cozzolino M. Stoumpos S, et al. Nephrol Dial Transplant. 2024 Sep 27;39(10):1710-1730. doi: 10.1093/ndt/gfae075. Nephrol Dial Transplant. 2024. PMID: 38573822 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical